Edwards appoints new ceo and cfo to drive future growth
The Board of Directors has announced changes to executive management
Nigel Hunton, who has been chief executive for the past four years, will take over the role of chairman with immediate effect.
Matthew Taylor will become ceo and David Smith, cfo. Taylor and Smith, who previously worked together in senior management positions at Jaguar Land Rover (JLR), and Ford Europe, bring extensive international leadership experience to Edwards.
Taylor was most recently the group chief executive officer of JC Bamford Excavators, the market leading global construction equipment company, where he worked from 2006. Previously he spent over 20 years with Ford, culminating in his role as md of Land Rover.
Smith brings 25 years blue-chip international experience with Ford and JLR, the last 13 years in cfo or ceo positions. Following his time as cfo of JLR, he went on to become ceo of the business from 2008-2010, during which time he steered it successfully through the complex ownership transition from Ford to Tata. Prior to JLR, David was finance and business strategy director, Premier Auto Group and Ford Europe.
Edwards employs around 3000 people worldwide in the design, manufacture and support of high technology vacuum and exhaust management equipment, as well as providing a wide range of other pumping technologies and related products. As chairman, Nigel Hunton will continue his active involvement in the business, advising the Board of Directors and the new ceo and focusing in particular on key customers, new product and market opportunities.
The Board is also announcing that, as part of these changes, the current finance director, Chris Bradley, has decided to leave the company. The Board would like to thank Chris for his very strong contribution to the business over the past 8 years.
Nigel Hunton, commented, “I am pleased to welcome Matthew and David to Edwards and look forward to working with them as we continue to deliver success for the company. 2010 is shaping up to be the best year in our 91 year history built on our restructuring actions, new products and new emerging markets. Edwards now has a broader and stronger management team to deliver successfully high technology solutions for our customers and capitalise on opportunities in all our markets”
You may also like
Manufacturing
BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech
The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Manufacturing
Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform
The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
Manufacturing
Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market
Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Sustainability
Marchesini Group solutions at Interpack 2026 to turn the challenges of the PPWR regulation into an opportunity
Düsseldorf (Germany) – The next edition of Interpack, scheduled to take place from 7 to 13 May in Düsseldorf, will devote significant space to the paradigms of the circular economy. The packaging industry is increasingly focusing on solutions designed to reduce environmental impact throughout the entire product lifecycle
Manufacturing
FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing
A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain